Abbisko Cayman Limited
和譽開曼有限責任公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2256)

VOLUNTARY ANNOUNCEMENT
ABBISKO THERAPEUTICS SHOWCASES SIX RESEARCH ADVANCES AT 2026 AACR, HIGHLIGHTING PAN-KRAS, 4TH GENERATION EGFR, AND SYNTHETIC LETHALITY APPROACHES

Abbisko Cayman Limited (the "**Company**", together with its subsidiaries, the "**Group**") hereby informs the shareholders and potential investors of the Company of the attached press release that Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**"), a subsidiary of the Company, announced that the Company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research ("**AACR**") 2026 Annual Meeting, held from April 17 to 22, 2026, in San Diego, USA. The presentations span multiple key innovation areas, including the pan-KRAS inhibitor ABSK211, the 4th generation EGFR inhibitor ABK-EGFR-1, the CDK4 selective inhibitor ABK-CDK4, the MTA-cooperative PRMT5 inhibitor ABSK131, as well as a ctDNA-based study investigating resistance mechanisms to the FGFR2/3 inhibitor ABSK061.

This is a voluntary announcement made by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Abbisko Cayman Limited
Dr. Xu Yao-Chang
Chairman

Shanghai, 23 April 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xu Yao-Chang, Dr. Yu Hongping and Dr. Ji Jing as executive directors; and Dr. Sun Piaoyang, Mr. Sun Hongbin and Ms. Chui Hoi Yam as independent non-executive directors.

Abbisko Therapeutics Showcases Six Research Advances at 2026 AACR, Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches

On April 23, 2026, Abbisko Therapeutics Co., Ltd. ("**Abbisko Therapeutics**") announced that the Company presented six latest preclinical and translational research findings in poster sessions at the American Association for Cancer Research ("**AACR**") 2026 Annual Meeting, held from April 17 to 22, 2026, in San Diego, USA.

The presentations span multiple key innovation areas, including the pan-KRAS inhibitor ABSK211, the 4th generation EGFR inhibitor ABK-EGFR-1, the CDK4 selective inhibitor ABK-CDK4, the MTA-cooperative PRMT5 inhibitor ABSK131, as well as a ctDNA-based study investigating resistance mechanisms to the FGFR2/3 inhibitor ABSK061.

pan-KRAS Inhibitor ABSK211

ABSK211 is a potent, highly selective, and orally bioavailable small-molecule pan-KRAS inhibitor developed by Abbisko Therapeutics. It demonstrates broad inhibitory activity against multiple KRAS mutations, addressing significant unmet medical needs in KRAS-driven cancers. At 2026 AACR, Abbisko presented preclinical data for both monotherapy and combination strategies of ABSK211.

Monotherapy: Broad and Potent Inhibition Across KRAS Mutations

KRAS mutations are highly prevalent across multiple cancers, including pancreatic (~90%), colorectal (~35%), and lung cancer (~25%). While several pan-KRAS inhibitors have entered clinical development, there remains a critical need for enhanced potency.

In preclinical studies, ABSK211 demonstrated several advantages:

- **Robust *in vitro* activity:** ABSK211 significantly reduced cell viability across multiple KRAS alterations (including G12, G13, Q61, and WT amplification) at sub-nanomolar to nanomolar concentrations. Meanwhile, ABSK211 displayed marginal inhibition in KRAS wild-type cell line with normal copy.

- **Strong *in vivo* efficacy:** Oral administration induced deep tumor regression in multiple KRAS G12V xenograft models, with robust target engagement.

- **Broad mutation coverage:** Consistent and significant antitumor activity was observed in models harboring KRAS G12D/C/S and G13D mutations.

These findings support the clinical advancement of ABSK211, which is currently undergoing IND-enabling studies.

Combination Therapy: Multi-Mechanistic Synergy Enhances Antitumor Activity

Combination therapy is widely considered a key strategy to improve treatment outcomes in KRAS-mutant cancers. ABSK211 demonstrated synergistic antitumor activity with multiple therapeutic agents:

- ***In vitro* synergy:** Significant anti-proliferative synergy with PRMT5 inhibitors across KRAS mutations; strong synergy observed with EGFR monoclonal antibodies and chemotherapy in KRAS G12D/G12V models.

- **Enhanced *in vivo* efficacy:** Combination regimens with PRMT5 inhibitors, cetuximab, immunotherapies, and chemotherapy showed superior tumor growth inhibition and improved durability compared to monotherapy.

These results demonstrate that ABSK211 can significantly enhance antitumor efficacy through multi-mechanistic synergy, supporting its further development in combination strategies.

4th Generation EGFR Inhibitor ABK-EGFR-1

ABK-EGFR-1 is a novel 4th generation EGFR inhibitor developed by Abbisko Therapeutics, specifically designed to target the EGFR C797S resistance mutation. It combines high selectivity with central nervous system ("**CNS**") penetration to address key clinical challenges following resistance to 3rd generation EGFR TKIs.

Targeting C797S-Mediated Resistance

The EGFR C797S mutation is a clinically validated mechanism of resistance to third-generation EGFR TKIs, with an estimated 51,000-146,000 cases annually worldwide. Currently, no approved therapies specifically target this mutation, representing a significant unmet clinical need.

Preclinical studies showed that ABK-EGFR-1:

- Exhibits high selectivity over wild-type EGFR and other kinases.

- Demonstrates significant in vivo antitumor activity in multiple EGFR C797S-driven xenograft models, effectively inhibiting tumor growth.

- Possesses excellent blood-brain barrier penetration and favorable drug-like properties.

These findings support further development of ABK-EGFR-1 as a next-generation targeted therapy for EGFR-resistant cancers, particularly for patients with brain metastases.

CDK4 Selective Inhibitor ABK-CDK4

ABK-CDK4 is a highly selective, brain-penetrant small-molecule CDK4 inhibitor developed by Abbisko Therapeutics. It is designed to selectively target CDK4, reduce CDK6-related toxicity, and expand treatment potential for patients with brain metastases.

Differentiation Through Selectivity and CNS Penetration

1st generation CDK4/6 inhibitors (e.g., palbociclib, ribociclib, and abemaciclib) have demonstrated clinical benefit in breast cancer, but CDK6 inhibition is associated with dose-limiting hematologic toxicities. In addition, 20-40% of breast cancer patients develop brain metastases, while current therapies have limited CNS exposure.

Preclinical studies showed that ABK-CDK4:

- **High selectivity:** Over 50-fold selectivity for CDK4 versus CDK6, potentially reducing CDK6-related toxicity.

- **CNS penetration:** Favorable CNS exposure (Kpuu > 0.5) and drug-like properties.

- **Antitumor activity:** Effective inhibition of Rb phosphorylation and tumor growth in HR+/HER2 – breast cancer models

These results suggest that ABK-CDK4 may overcome key limitations of current CDK4/6 inhibitors and provide a differentiated therapeutic option.

MTA-cooperative PRMT5 inhibitor ABSK131

ABSK131 is a potent and selective small-molecule MTA-cooperative PRMT5 inhibitor developed by Abbisko Therapeutics, targeting MTAP-deleted tumors, and is currently in clinical development.

Broad Synergy Across Multiple Therapeutic Modalities

MTAP homozygous deletion occurs in approximately 10-15% of solid tumors and frequently co-exists with oncogenic drivers such as KRAS and EGFR. In addition, MTAP abnormities are associated with poor prognosis following standard-of-care therapies across multiple cancer types. Therefore, there remains a significant unmet need for novel and effective combination therapies centered on MTA-cooperative PRMT5 inhibitor for MTAP-deleted tumors, with the potential to enable precision patient stratification and deliver synergistic therapeutic benefits.

Preclinical studies demonstrated that ABSK131 exhibits strong synergistic activity with multiple therapies:

- **Combination with KRAS inhibitors:** Enhanced tumor growth inhibition in KRAS-mutant, MTAP-deleted models when combined with AMG 510 (KRAS G12C inhibitor) or ABSK141 (KRAS G12D inhibitor).

- **Combination with EGFR inhibitors:** Improved anti-proliferative and in vivo antitumor activity in EGFR-mutant, MTAP-deleted NSCLC models when combined with osimertinib.

- **Combination with MAT2A inhibitors:** Consistent synergistic effects across multiple tumor models when combined with IDE397.

- **Chemotherapy:** Synergistic activity observed both in vitro and in vivo when combined with carboplatin in NSCLC models.

These findings support ABSK131 as a potential backbone therapy for combination strategies in MTAP-deleted tumors.

FGFR2/3 Inhibitor ABSK061

ABSK061 is a highly potent and selective small-molecule FGFR2/3 inhibitor developed by Abbisko Therapeutics. It has demonstrated encouraging efficacy and safety in Phase I studies and is currently being evaluated in a Phase II trial for gastric cancer.

ctDNA Analysis Reveals Resistance Mechanisms

Acquired resistance remains a major challenge limiting the long-term benefit of targeted therapies. Using ctDNA-based next-generation sequencing ("**NGS**"), Abbisko conducted longitudinal genomic analyses comparing baseline and progression samples to elucidate resistance mechanisms to ABSK061:

On-target resistance: Polyclonal acquired FGFR2 mutations in the FGFR2 kinase domain were commonly observed in gastric cancer and cholangiocarcinoma.

Off-target resistance: FGFR2 – Altered NSCLC was prone to develop acquired alterations in genes involved in RTK/RAS pathways.

These findings provide important molecular insights into resistance mechanisms and inform the design of future combination and sequential treatment strategies.

At 2026 AACR, Abbisko Therapeutics showcased the latest preclinical and translational research advances across multiple pipeline programs, demonstrating its strong capabilities in drug discovery and development. As these programs continue to advance into clinical stages, the company is further strengthening its globally competitive R&D platform. Looking ahead, Abbisko Therapeutics will continue to focus on addressing unmet medical needs and accelerating the translation of innovative discoveries into clinical applications, with the goal of delivering more first-in-class and best-in-class therapies to patients worldwide.

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.

Forward-Looking Statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.